today. Chris. Good us everyone, and for you, Thank thank afternoon, you joining
preserving and advanced XXXX, and supporting following operating their customers, to us research and our projects and and have pandemic in safety all and and our our allowed employees I on personally during globally, the and core priorities to we position families, COVID-XX the discuss minutes global quarter and customers results, accounts, few implemented a Before our created spend companies, conventional and the XXXX. year unprecedented our key stay maintaining want an development response protecting plans past including both of protecting focused fourth we By prioritized health reflecting strategic uncertain operate ways jobs times. strong the year our The financial employees pandemic the professionally. challenged
XXXX I been never have and more with believe a prospects exited that company As a result, capable we stronger. more fundamental efficient
and well rapidly our MIGS partner of clinical been changing to and a of them cross-linking, customers we help the initiatives. support, these honored corneal navigate and through prepare expansion customer pioneer various our to environment corporate case confident the training, including beyond deepen educational have have for I'm efforts with future proctoring investigators relationships us implementation customer COVID-XX. As programs, and virtual and the digital and that helped
to year the and patients our proud serve of worldwide. world-class vision pandemic. this glaucoma, they doing Overall, that and positioned pipeline create each are innovation worldwide treatment disease. performance moving uniquely enrich marketplace the mission full these corneal of leader made to doing our disrupt pioneering advance existing advancing of same treatment ahead we a paradigms, conventional with to thank and speed worldwide Within team's commercial health global and resiliency novel of patients alternatives we and to during customers lives Finally, I'm today. the these care to has everything platforms drive the very us to are create expertise strive care execution I In the past discipline, for our for skilled steadfast standard the retinal and across development that needs so, MIGS leader the areas, of of want dedication
codes preservation times, Our our designed franchise the bolstered and of past the market implemented next-generation for initiatives, encouraging also to convertible we during and invest regulatory we trends the least, integration, the growth markets beginning sales but only ability unprecedented five, iStent U.S. four, margins, ability progress not reflection creation we advanced but and we the not in plans, corneal it's this our such including the we further continue aggressively of starts India; strategic opportunities; to current sales addressable but markets; year. and expansion environment, market last a on response device key we our to advanced believe W and that in through two, our proprietary to stand-alone expand certainly ability gross our by long-term systems recovery the our industry-leading as pipeline executed secured financially record development strengthen expanding sales; global support to has iDose towards we evidenced our our XXXX debt a financing plans international our select to we balance opportunities new market to operating key six, by year three inject illustrates not a broader future launched and new in strong access growth; makes; our health new we approvals three, pipeline reported $XXX upgrade successfully make Consider and strong in over market reimbursement million key Japan significantly sheet, with vision. continued one, CPT only executed spending and glaucoma accomplishments: category of execute transformation Photrexa international disciplined strong and Australia, effective ongoing market also
As and you algorithm provide progression needs. customer development key continued on commercial infrastructure our leverage goal deep this color novel most our on of of full is portfolio expertise pipeline. that to to the our is of a strategy of know, the solutions meet A delivering
eight interim to from XX% subjects TR Interestingly, minutes XX approximately pharmaceutical iDose implant XX%. IOP glaucoma millimeters months. mercury drug and new travoprost first delivery recently programs: announced achieved least analysis two this from baseline infinite. XX-month like few arms we a of over XX at iDose iStent the subset of data shared demonstrate glaucoma baseline our IOP robust TR, the I'd for to Phase months with iDose continuing regimens. and highlighting reductions medication clinical for to pipeline to seven reductions showed and So our iDose to ongoing a Starting underscores key year to non-adherence lowering data exciting earlier spend safely magnitude The over of we this month XX on average or at powerful robust topical is XX% what of announce trial significant that delighted believe years to the showed of were nearly tackle further least problem compliance sustained of patient glaucoma to analysis IIb technology results compelling our multiple XX/X of both the compelling therapy provide potential of
per twice to received terminal daily drops these were XX-month implant control arm eye. the results iDose that eye or compared Importantly, drops single the achieved evaluation period with X,XXX a over nearly
solution believe durable our a conjunctival to safety no reminder, is powerful profile traditional the a cell ophthalmic there As is Phase And either endothelial iDose. release effective into with no corneal alternatives implanted TR very need and avoid pharmaceutical XX-month sustained the hyperemia reported data and recent readout medications. arm. II corneal a events about date procedure interim no and clinically excitement an We commercial unmet clinical favorable adverse loss, within potential the events this serious migration trabecular network adverse strong iDose of important to reaffirms and topical through data for demonstrated safe, iDose the facile appetite to prospects of significant community most in
progress iDose underscores other powerful delivery targeting approval The NDA in XX-month market. ongoing The will are Phase in far our of critical ocular TR produce iDose the clinical trial thus another this program, We sustained novel and to III drug III technology therapies we potential for data XXXX. and of XXXX, generations glaucoma future platform available promising for submission enrollment continue to this in mark which technology are potentially our the diseases. towards FDA confidence our this Phase iDose completion expected anticipated in TR step to support results in bringing to for
implants, and also are pharmaceutical which to As designed solutions. that durations TR, for efficacy such, TR finalized late-stage expand extended-release develop provide to nearly future resources is next-generation we mind, capacity the designs invest in factor to and a iDose to continue our the we development size iDose even known twice is form similar extend capabilities TREX, as original iDose in iDose with to to longer. With development drug in
with for appropriate most the expeditious FDA near novel and We be engaging product. the pathway will the to in determine regulatory this future
assessing in agreement platform. We in classes synergistically be iDose the that are and may are research currently which seeking with used positive multiple showing in ROCK same in Western, treatment are been compounds, results development ROCK drug animal models. inhibitors we additional pivotal implants D. pressure with also conjunction models, when a prostaglandins U.S. our Through shown for conjunction studies. these have used as and reducing lead intraocular powerful we're establishing candidates in with prototype in
iStent excited same burden, more also designed patients, announced in infinite's profile and disease a our were was subjects while medication infections, reduction achieved data IOP to enrolled months, option. recently treatment we Subjects iStent to reduction at study the of IDE of of no a late-stage device-related an of on medication months. profile of the through XX%. surgeons with infinite, or in achieving least risk-benefit we or achieved progression three favorably a IOP XX profile pairing at XX will are When XX% on strong in greater XX XX% and lower or Pivotal Moving XX-month in reductions ophthalmic results than that the system subjects highly with stand-alone showed that on view mean average interventions use burden procedure explants, XX% with prior month month or new two compelling reported failed favorable very XX% for mean advanced for have surgeries, pivotal strong stent the medications hypotony with as believe these glaucoma subjects the safety three
in approval We XXXX. infinite iStent continue late to FDA of target
PRESERFLO Pharmaceutical's MicroShunt, we these the implant elegant for pipeline also glaucoma potential ab-externo preparations Beyond U.S. surgical an management. important Santen glaucoma early in launch commercial late-stage programs, remain for of
ramp opportunity continue this commercial our an approval and for up We anticipated to commercial preparations FDA promising ahead launch. of
treatment a study Epi-On release patients. we in of is baseline met curvature to keratoconus the curvature, corneal announcing events of reported maximum The based placebo-controlled arm, for in study's Kmax. Epi-On demonstrated tolerated diopter study's placebo We Most halt transient device improve endpoint on results treatment improvement positive are and press topography, be in first generally times. Phase issued underscore resulting efficacy minimally recovery this our corneal one efficacy and measurement delivery majority randomized, development to that primary pivotal therapy or while complementary corneal mean statistically the the the treatment non-invasive positive Kmax NDA objective or III Phase this placebo reduce well endpoint. control bioactivated X.X recently disease III Epi-On primary and patient disease invasive Within progression and with drug the highly significant progression. steepest targeting the were in with XXXX. support observed arm. an of of the mild was corneal announce cross-linking progression where Kmax statistically may support importantly diopters that procedure was meeting reduce needs ability XXXX, separate X.X and mean from physicians III from are patients Epi-On Phase arm visco an iLink and was iPrime, the diopters to the a community At new showed in We're are results also treatment baseline designed in the six approval These a the a of significant of to to investigational late-stage to announced a compared U.S. view Corneal denotes system of increasing the afternoon our excited keratoconus alternative truly next-generation from a that months, Kmax worsening designed control mean multi-center, provide in that adverse nature. shorten to Health, of FDA times, Kmax ophthalmic keratoconus, and in effect steepening therapy. we we positive improvement corneal submission expected for results results comfort the The Epi the further
these retina. to our invest Beyond to in we near and continue and medium-term including stage key R&D also opportunities, eye earlier in dry programs, advance
opportunities these stages, we preclinical are these with initial While we're the remain excited in within developmental demonstrating programs. progress
our our our Our offense pipeline enable towards been pleased out by commercial play remain recovery a continued has business as the the this, quarter. fundamentally the expanding to trends with that the our over enterprise provide markets expanding systems, related time. on our significantly with strong peak to our strong upgrading flexibility sheet in And clinical to supporting the Glaukos by commercial of expertise, global we've balance pharmaceutical strengthening the becoming transform programs To speaking realities. dynamics built and us we COVID core of financial R&D through ability progress have programs, pandemic they as the realities, infrastructure, our since addressable advancing fourth
navigating $XX.X I've procedure pleased sales encouraged and million I'm and report our ASCs While of how net exceeded are by offices, quarter corneal glaucoma And fourth that physician been globally. somewhat remain franchise new trends expectations volatile, to our normal. health across hospitals recovery this
the ophthalmic in procedural proof feedback iStent an very reaffirms inject iStent of the in and The the confidence the stent same launch is our offer During and iStent to remain designed established with and results upon W deliver iStent predictability. inject and to the visualization, commenced positive benefits designed inject full-scale foundation real-world of efficacy safety inject quarter, builds surgeons added we the platform of W fourth and implantation The U.S. official W inject early for optimize streamline approval us long-term W our and iStent iStent well Japan, Australia, and to more technology. of key also broadly our various iStent iStent stand-alone across regulatory India positions our launched key adds in approval approval international glaucoma including commercial for in Japan W growth, inject many in inject Australia. number We've a prospects including in indication regulatory that international continued of market and of for accomplishments and many our markets, important franchise countries, this European This inject initiatives. progress access in XXXX the
customer-friendly value Finally, plan implementing firmly finally, but reimbursement, corneal future broadly Not this and to include establish economics professionals patients procedure. our continue XXXX, health we health across of increased in the development referral which systems; engine we starts, to support time training announced the in to optometric ahead only as of are investing To to further the treatment, our importantly a course of commercial to the healthcare franchise we diagnosis optimizing programs the account Health solidify community, corneal strides diagnosis iLink ophthalmic pattern and over are the initial made cross-linking of advancing the this expand resonating. the strategies drive to condition, new we've quarter, keratoconus new Corneal significant sign We're progress, U.S. more of new in driving strategies cost execute continue Health sales initiatives, deal, the commercial and Corneal that programs important savings we streamlining market debilitating the U.S. growth to established introduced see our encouraging from awareness of fourth on and and on targets organization. for our record pleased to team. at our we for opportunistically an Photrexa on another
unlocking and about early excited ahead. opportunity encouraged we're While we with remain full of performance organization's the combined the this potential, the stages in
vision summary, prepared profitability So next that and significantly we're and unique a a drive drive opportunities cadence robust market care our of creating innovation leader to over in can decade. expand the growth sustainable
in execute While advance on me leaves treatment uncertainties for worldwide. to transform we the with benefit we, near-term the cautious of mission and on strong patients ability our and course, built the our the of team confident eye chronic foundation diseases plan to remain COVID-XX, of associated the our
call I'm Joe? that, going XXXX to turn discuss results. quarter with to Joe financial our fourth to So the over
